Electrochaea sells biomethane reactor to Again A/S
Archaeal Power-to-biomethan producer Electrochaea GmbH has sold a BioCat bioreactor to the Danish CCU specialist Again A/S.
Flindr Therapeutics BV secures €20m Series A financing
Oss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.
Nordic Bioproducts Group opens its first production facility
Finnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology
Swiss Biotech Report reporting record turnover
The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn.<span style="mso-ansi-language:EN-US" lang="EN-US"> Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and […]
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Ipsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.
SeaBeLife to use €1.5m award for drug development
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
SeaBeLifeSeabelife SAS to develop next-gen dry AMD drug
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
Seabelife SAS to develop next-gen dry AMD drug
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
AmphiStar BV secures €6m to expand production
Waste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).
Naobios and Sumagen partner to develop HIV vaccine
Vaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.<br /> <br /><b><br /></b>